While the scale of the currency headwinds in Roche’s first-quarter financial update caught many off guard, the company’s earnings call still featured much discussion on a pivotal pipeline prospect: the oral SERD drug giredestrant. The drug carries blockbuster ambitions, yet its commercial path has been clouded by imperfect clinical data.